Supplementary materials: Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

These are peer-reviewed supplementary materials for the article 'Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus' published in the Journal of Comparative Effectiveness Research.Appendix A: Systematic Literature ReviewTable S1: Summary of inclusion and exclusion criteria for the systematic literature review.Appendix B: PRISMA Flow DiagramFigure S1: PRISMA flow diagram. Appendix C: Feasibility AssessmentTable S2: Overview of feasibility assessment by outcome.Appendix D: STC Analysis: Additional Details and Sensitivity AnalysesTable S3: Factors adjusted in each base case STC analysis.Figure S2: SLEDAI reduction STC sensitivity analysis: Inclusion of MUSEFigure S3: SRI(4) response STC sensitivity analysis: Inclusion of MUSEFigure S4: BILAG flares STC sensitivity analysis: Inclusion of MUSEFigure S5: OCS reduction STC sensitivity analysis: Inclusion of MUSEAim: Assess the comparative efficacy of anifrolumab 300 mg versus belimumab 10 mg/kg in adults with moderate-to-severe systemic lupus erythematosus (SLE) receiving standard therapy. Patients and methods: Population-adjusted simulated treatment comparisons (primary analyses) and matching-adjusted indirect comparisons (supporting analyses) were conducted using individual patient data from TULIP-1/TULIP-2 and summary-level data from BLISS-52/BLISS-76. Results: Compared with belimumab-treated patients, anifrolumab-treated patients were more than twice as likely to achieve a reduction of four or more points in SLE Disease Activity Index 2000 score (simulated treatment comparison odds ratio: 2.47; 95% CI: 1.16–5.25) and SLE Responder Index-4 response (odds ratio: 2.61; 95% CI: 1.22–5.58) at 52 weeks. Conclusion: Patients with moderate-to-severe SLE are more likely to achieve an improvement in disease activity with anifrolumab than with belimumab.

本数据集为发表于《比较疗效研究杂志》的论文《系统性红斑狼疮成人患者中anifrolumab疗效与belimumab疗效的间接比较》的同行评审补充材料。附录A：系统文献综述表S1：系统文献综述的纳入和排除标准概要。附录B：PRISMA流程图图S1：PRISMA流程图。附录C：可行性评估表S2：按结果概述可行性评估。附录D：STC分析：额外细节和敏感性分析表S3：每个基线STC分析中调整的因素。图S2：SLEDAI减少的STC敏感性分析：纳入MUSE。图S3：SRI(4)反应的STC敏感性分析：纳入MUSE。图S4：BILAG复发的STC敏感性分析：纳入MUSE。图S5：OCS减少的STC敏感性分析：纳入MUSE。研究目标：评估anifrolumab 300 mg与belimumab 10 mg/kg在接受标准治疗的轻至重度系统性红斑狼疮（SLE）成人患者中的比较疗效。研究方法：采用TULIP-1/TULIP-2的研究个体患者数据和BLISS-52/BLISS-76的总结级数据，进行了人口调整的模拟治疗比较（主要分析）和匹配调整的间接比较（辅助分析）。研究结果：与接受belimumab治疗的病人相比，接受anifrolumab治疗的病人在52周时，实现SLE疾病活动指数2000评分减少四点或以上的可能性超过两倍（模拟治疗比较的比值比：2.47；95%置信区间：1.16–5.25），以及实现SLE反应指数-4反应的可能性为2.61（比值比：2.61；95%置信区间：1.22–5.58）。研究结论：轻至重度SLE患者更有可能通过anifrolumab而非belimumab实现疾病活动的改善。